Development of NGR-based anti-cancer agents for targeted therapeutics and imaging

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2012, Pages 76-86

  Wang, Rongsheng E ^a   Niu, Youhong ^b   Wu, Haifan ^b   Hu, Yaogang ^b   Cai, Jianfeng ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Aminopeptidase N (APN CD13); Angiogenesis; Asn Gly Arg (NGR); Cancer; Clinical trial; Drug delivery; Imaging

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTYLGLYCYLARGININE PEPTIDE; CELL PENETRATING PEPTIDE; CISPLATIN; DOCETAXEL; DOXORUBICIN; LYMPHOTOXIN; MELPHALAN; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; PENTETIC ACID; PENTETIC ACID GD 3; POLYLACTIDE; QUANTUM DOT; RECOMBINANT ALPHA2A INTERFERON; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; FLUORESCENCE; GENE THERAPY; HUMAN; IMAGING SYSTEM; LUNG ADENOCARCINOMA; MESOTHELIOMA; NONHUMAN; PROSTATE CANCER; TUMOR DIAGNOSIS; TUMOR VASCULARIZATION;

EID: 84855267541     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012798764714     Document Type: Article

References (132)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA. Cancer J. Clin., 2008, 58, 71-96.
2. Siddik, Z.H.; Mehta, K.; SpringerLink (Online service): Drug Resistance in Cancer Cells.; Springer-Verlag: New York, 2009.
3. Bruckheimer, E.M.; Fazenbaker, C.A.; Gallagher, S.; Mulgrew, K.; Fuhrmann, S.; Coffman, K.T.; Walsh, W.; Ready, S.; Cook, K.; Damschroder, M.; Kinch, M.; Kiener, P.A.; Woods, R.; Gao, C.; Dall'Acqua, W.; Wu, H.; Coats, S. Antibody-dependent cellmediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia, 2009, 11, 509-517.
4. He, X.; Na, M.H.; Kim, J.S.; Lee, G.Y.; Park, J.Y.; Hoffman, A.S.; Nam, J.O.; Han, S.E.; Sim, G.Y.; Oh, Y.K.; Kim, I.S.; Lee, B.H. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Mol. Pharm., 2011, 8, 430-438.
5. Lowery, A.; Onishko, H.; Hallahan, D.E.; Han, Z. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J. Control. Release, 2011, 150, 117-124.
6. Nakagawa, O.; Ming, X.; Huang, L.; Juliano, R.L. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J. Am. Chem. Soc., 2010, 132, 8848-8849.
7. Phongpradist, R.; Chittasupho, C.; Okonogi, S.; Siahaan, T.; Anuchapreeda, S.; Ampasavate, C.; Berkland, C. LFA-1 on leukemic cells as a target for therapy or drug delivery. Curr. Pharm. Des., 2010, 16, 2321-2330.
8. Sanchez-Martin, D.; Cuesta, A.M.; Fogal, V.; Ruoslahti, E.; Alvarez-Vallina, L. The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J. Biol. Chem., 2011, 286, 5197-5203.
9. Bolhassani, A.; Safaiyan, S.; Rafati, S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer, 2011, 10, 3.
10. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000, 65, 271-284.
11. Abdollahi, A.; Folkman, J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat., 2010, 13, 16-28.
12. Ebos, J.M.; Kerbel, R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol., 2011, 8, 316.
13. Keshet, E.; Ben-Sasson, S.A. Anticancer drug targets: approaching angiogenesis. J. Clin. Invest., 1999, 104, 1497-1501.
14. Corti, A.; Pastorino, F.; Curnis, F.; Arap, W.; Ponzoni, M.; Pasqualini, R. Targeted drug delivery and penetration into solid tumors. Med. Res. Rev., 2011.
15. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279, 377-380.
16. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R.A.; Shapiro, L.H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000, 60, 722-727.
17. Curnis, F.; Arrigoni, G.; Sacchi, A.; Fischetti, L.; Arap, W.; Pasqualini, R.; Corti, A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res., 2002, 62, 867-874.
18. Majhen, D.; Gabrilovac, J.; Eloit, M.; Richardson, J.; Ambriovic-Ristov, A. Disulfide bond formation in NGR fiber-modified adenovirus is essential for retargeting to aminopeptidase N. Biochem. Biophys. Res. Commun., 2006, 348, 278-287.
19. Colombo, G.; Curnis, F.; De Mori, G.M.; Gasparri, A.; Longoni, C.; Sacchi, A.; Longhi, R.; Corti, A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem., 2002, 277, 47891-47897.
20. Negussie, A.H.; Miller, J.L.; Reddy, G.; Drake, S.K.; Wood, B.J.; Dreher, M.R. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J. Control. Release, 2010, 143, 265-273.
21. Metaferia, B.B.; Rittler, M.; Gheeya, J.S.; Lee, A.; Hempel, H.; Plaza, A.; Stetler-Stevenson, W.G.; Bewley, C.A.; Khan, J. Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry. Bioorg. Med. Chem. Lett., 2010, 20, 7337-7340.
22. Di Matteo, P.; Curnis, F.; Longhi, R.; Colombo, G.; Sacchi, A.; Crippa, L.; Protti, M.P.; Ponzoni, M.; Toma, S.; Corti, A. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol. Immunol., 2006, 43, 1509-1518.
23. Corti, A.; Ponzoni, M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann. N. Y. Acad. Sci., 2004, 1028, 104-112.
24. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol., 2000, 18, 1185-1190.
25. Gasparri, A.; Moro, M.; Curnis, F.; Sacchi, A.; Pagano, S.; Veglia, F.; Casorati, G.; Siccardi, A.G.; Dellabona, P.; Corti, A. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res., 1999, 59, 2917-2923.
26. Clauss, M.; Murray, J.C.; Vianna, M.; de Waal, R.; Thurston, G.; Nawroth, P.; Gerlach, H.; Bach, R.; Familletti, P.C.; Stern, D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J. Biol. Chem., 1990, 265, 7078-7083.
27. Kristensen, C.A.; Nozue, M.; Boucher, Y.; Jain, R.K. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br. J. Cancer, 1996, 74, 533-536.
28. Nawroth, P.; Handley, D.; Matsueda, G.; De Waal, R.; Gerlach, H.; Blohm, D.; Stern, D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med., 1988, 168, 637-647.
29. Nawroth, P.P.; Stern, D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 1986, 163, 740-745.
30. Palladino, M.A., Jr.; Shalaby, M.R.; Kramer, S.M.; Ferraiolo, B.L.; Baughman, R.A.; Deleo, A.B.; Crase, D.; Marafino, B.; Aggarwal, B.B.; Figari, I.S.; et al. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol., 1987, 138, 4023-4032.
31. van der Veen, A.H.; de Wilt, J.H.; Eggermont, A.M.; van Tiel, S.T.; Seynhaeve, A.L.; ten Hagen, T.L. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br. J. Cancer, 2000, 82, 973-980.
32. de Wilt, J.H.; ten Hagen, T.L.; de Boeck, G.; van Tiel, S.T.; de Bruijn, E.A.; Eggermont, A.M. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br. J. Cancer, 2000, 82, 1000-1003.
33. Suzuki, S.; Ohta, S.; Takashio, K.; Nitanai, H.; Hashimoto, Y. Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factoralpha in mice. Int. J. Cancer, 1990, 46, 1095-1100.
34. van Laarhoven, H.W.; Gambarota, G.; Heerschap, A.; Lok, J.; Verhagen, I.; Corti, A.; Toma, S.; Gallo Stampino, C.; van der Kogel, A.; Punt, C.J. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest. New Drugs, 2006, 24, 27-36.
35. Curnis, F.; Sacchi, A.; Corti, A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest., 2002, 110, 475-482.
36. Sacchi, A.; Gasparri, A.; Gallo-Stampino, C.; Toma, S.; Curnis, F.; Corti, A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factoralpha. Clin. Cancer Res., 2006, 12, 175-182.
37. Bertilaccio, M.T.; Grioni, M.; Sutherland, B.W.; Degl'Innocenti, E.; Freschi, M.; Jachetti, E.; Greenberg, N.M.; Corti, A.; Bellone, M. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate, 2008, 68, 1105-1115.
38. Mizuguchi, H.; Nakagawa, T.; Toyosawa, S.; Nakanishi, M.; Imazu, S.; Nakanishi, T.; Tsutsumi, Y.; Nakagawa, S.; Hayakawa, T.; Ijuhin, N.; Mayumi, T. Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res., 1998, 58, 5725-5730.
39. Kircheis, R.; Wightman, L.; Kursa, M.; Ostermann, E.; Wagner, E. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther., 2002, 9, 731-735.
40. Zarovni, N.; Monaco, L.; Corti, A. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides. Hum. Gene Ther., 2004, 15, 373-382.
41. van Laarhoven, H.W.; Fiedler, W.; Desar, I.M.; van Asten, J.J.; Marreaud, S.; Lacombe, D.; Govaerts, A.S.; Bogaerts, J.; Lasch, P.; Timmer-Bonte, J.N.; Lambiase, A.; Bordignon, C.; Punt, C.J.; Heerschap, A.; van Herpen, C.M. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin. Cancer Res., 2010, 16, 1315-1323.
42. Gregorc, V.; Citterio, G.; Vitali, G.; Spreafico, A.; Scifo, P.; Borri, A.; Donadoni, G.; Rossoni, G.; Corti, A.; Caligaris-Cappio, F.; Del Maschio, A.; Esposito, A.; De Cobelli, F.; Dell'Acqua, F.; Troysi, A.; Bruzzi, P.; Lambiase, A.; Bordignon, C. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur. J. Cancer, 2010, 46, 198-206.
43. Gregorc, V.; Zucali, P.A.; Santoro, A.; Ceresoli, G.L.; Citterio, G.; De Pas, T.M.; Zilembo, N.; De Vincenzo, F.; Simonelli, M.; Rossoni, G.; Spreafico, A.; Grazia Vigano, M.; Fontana, F.; De Braud, F.G.; Bajetta, E.; Caligaris-Cappio, F.; Bruzzi, P.; Lambiase, A.; Bordignon, C. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J. Clin. Oncol., 2010, 28, 2604-2611.
44. Santoro, A.; Rimassa, L.; Sobrero, A.F.; Citterio, G.; Sclafani, F.; Carnaghi, C.; Pessino, A.; Caprioni, F.; Andretta, V.; Tronconi, M.C.; Finocchiaro, G.; Rossoni, G.; Zanoni, A.; Miggiano, C.; Rizzardi, G.P.; Traversari, C.; Caligaris-Cappio, F.; Lambiase, A.; Bordignon, C. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur. J. Cancer, 2010, 46, 2746-2752.
45. Mammoliti, S.; Andretta, V.; Bennicelli, E.; Caprioni, F.; Comandini, D.; Fornarini, G.; Guglielmi, A.; Pessino, A.; Sciallero, S.; Sobrero, A.F.; Mazzola, G.; Lambiase, A.; Bordignon, C. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Ann.Oncol., 2011, 22, 973-978.
46. Santoro, A.; Pressiani, T.; Citterio, G.; Rossoni, G.; Donadoni, G.; Pozzi, F.; Rimassa, L.; Personeni, N.; Bozzarelli, S.; Rossoni, G.; Colombi, S.; De Braud, F.G.; Caligaris-Cappio, F.; Lambiase, A.; Bordignon, C. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br. J. Cancer, 2010, 103, 837-844.
47. Gregorc, V.; De Braud, F.G.; De Pas, T.M.; Scalamogna, R.; Citterio, G.; Milani, A.; Boselli, S.; Catania, C.; Donadoni, G.; Rossoni, G.; Ghio, D.; Spitaleri, G.; Ammannati, C.; Colombi, S.; Caligaris-Cappio, F.; Lambiase, A.; Bordignon, C. Phase I study of NGRhTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin. Cancer Res., 2011, 17, 1964-1972.
48. Gregorc, V.; Santoro, A.; Bennicelli, E.; Punt, C.J.; Citterio, G.; Timmer-Bonte, J.N.; Caligaris Cappio, F.; Lambiase, A.; Bordignon, C.; van Herpen, C.M. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br. J. Cancer, 2009, 101, 219-224.
49. Gutterman, J.U. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 1198-1205.
50. Silver, R.T.; Woolf, S.H.; Hehlmann, R.; Appelbaum, F.R.; Anderson, J.; Bennett, C.; Goldman, J.M.; Guilhot, F.; Kantarjian, H.M.; Lichtin, A.E.; Talpaz, M.; Tura, S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 1999, 94, 1517-1536.
51. Pestka, S.; Langer, J.A.; Zoon, K.C.; Samuel, C.E. Interferons and their actions. Annu. Rev. Biochem., 1987, 56, 727-777.
52. Motzer, R.J.; Murphy, B.A.; Bacik, J.; Schwartz, L.H.; Nanus, D.M.; Mariani, T.; Loehrer, P.; Wilding, G.; Fairclough, D.L.; Cella, D.; Mazumdar, M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol., 2000, 18, 2972-2980.
53. Wadler, S. The role of interferons in the treatment of solid tumors. Cancer, 1992, 70, 949-958.
54. Caraceni, A.; Gangeri, L.; Martini, C.; Belli, F.; Brunelli, C.; Baldini, M.; Mascheroni, L.; Lenisa, L.; Cascinelli, N. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer, 1998, 83, 482-489.
55. Yamada, S.; Takada, K.; Tsuchida, S.; Teramoto, A.; Shishiba, Y. A study of anterior pituitary hormones secretion in patients with glioma receiving interferon-beta treatment. Endocr. J., 1996, 43, 335-338.
56. Meng, J.; Yan, Z.; Wu, J.; Li, L.; Xue, X.; Li, M.; Li, W.; Hao, Q.; Wan, Y.; Qin, X.; Zhang, C.; You, Y.; Han, W.; Zhang, Y. Highyield expression, purification and characterization of tumortargeted IFN-alpha2a. Cytotherapy, 2007, 9, 60-68.
57. Zhang, B.; Gao, B.; Dong, S.; Zhang, Y.; Wu, Y. Anti-tumor efficacy and pre-clinical immunogenicity of IFNalpha2a-NGR. Regul. Toxicol. Pharmacol., 2011, 60, 73-78.
58. Meng, J.; Yan, Z.; Wu, Y.; Gao, M.; Li, W.; Gao, F.; Wang, H.; Han, W.; Zhang, Y. Preclinical safety evaluation of IFNalpha2a-NGR. Regul. Toxicol. Pharmacol., 2008, 50, 294-302.
59. Morrissey, J.H.; Macik, B.G.; Neuenschwander, P.F.; Comp, P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood, 1993, 81, 734-744.
60. Ran, S.; Gao, B.; Duffy, S.; Watkins, L.; Rote, N.; Thorpe, P.E. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res., 1998, 58, 4646-4653.
61. Liu, C.; Huang, H.; Donate, F.; Dickinson, C.; Santucci, R.; El-Sheikh, A.; Vessella, R.; Edgington, T.S. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res., 2002, 62, 5470-5475.
62. Nilsson, F.; Kosmehl, H.; Zardi, L.; Neri, D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res., 2001, 61, 711-716.
63. Huang, X.; Molema, G.; King, S.; Watkins, L.; Edgington, T.S.; Thorpe, P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 1997, 275, 547-550.
64. Schwoppe, C.; Kessler, T.; Persigehl, T.; Liersch, R.; Hintelmann, H.; Dreischaluck, J.; Ring, J.; Bremer, C.; Heindel, W.; Mesters, R.M.; Berdel, W.E. Tissue-factor fusion proteins induce occlusion of tumor vessels. Thromb. Res., 2010,125 Suppl 2, S143-150.
65. Dreischaluck, J.; Schwoppe, C.; Spieker, T.; Kessler, T.; Tiemann, K.; Liersch, R.; Schliemann, C.; Kreuter, M.; Kolkmeyer, A.; Hintelmann, H.; Mesters, R.M.; Berdel, W.E. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Int. J. Oncol., 2010, 37, 1389-1397.
66. Bieker, R.; Kessler, T.; Schwoppe, C.; Padro, T.; Persigehl, T.; Bremer, C.; Dreischaluck, J.; Kolkmeyer, A.; Heindel, W.; Mesters, R.M.; Berdel, W.E. Infarction of tumor vessels by NGRpeptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood, 2009, 113, 5019-5027.
67. Lei, H.; Cao, P.; Miao, G.; Lin, Z.; Diao, Z. Expression and functional characterization of tumor-targeted fusion protein composed of NGR peptide and 15-kDa actin fragment. Appl. Biochem. Biotechnol., 2010, 162, 988-995.
68. Meng, J.; Ma, N.; Yan, Z.; Han, W.; Zhang, Y. NGR enhanced the anti-angiogenic activity of tum-5. J. Biochem., 2006, 140, 299-304.
69. O'Reilly, M.S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W.S.; Flynn, E.; Birkhead, J.R.; Olsen, B.R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88, 277-285.
70. Yokoyama, Y.; Ramakrishnan, S. Improved biological activity of a mutant endostatin containing a single amino-acid substitution. Br. J. Cancer, 2004, 90, 1627-1635.
71. Yokoyama, Y.; Ramakrishnan, S. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth. Cancer, 2005, 104, 321-331.
72. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 2005, 4, 307-320.
73. Reedijk, J. Improved understanding in platinium antitumour chemistry. Chem. Commun., 1996, 801-806.
74. Cubeddu, L.X.; Hoffmann, I.S.; Fuenmayor, N.T.; Finn, A.L. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N. Engl. J. Med., 1990, 322, 810-816.
75. Mukhopadhyay, S.; Barnes, C.M.; Haskel, A.; Short, S.M.; Barnes, K.R.; Lippard, S.J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug. Chem., 2008, 19, 39-49.
76. Ndinguri, M.W.; Solipuram, R.; Gambrell, R.P.; Aggarwal, S.; Hammer, R.P. Peptide targeting of platinum anti-cancer drugs. Bioconjug. Chem., 2009, 20, 1869-1878.
77. Bessalle, R.; Kapitkovsky, A.; Gorea, A.; Shalit, I.; Fridkin, M. All-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett., 1990, 274, 151-155.
78. Javadpour, M.M.; Juban, M.M.; Lo, W.C.; Bishop, S.M.; Alberty, J.B.; Cowell, S.M.; Becker, C.L.; McLaughlin, M.L. De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem., 1996, 39, 3107-3113.
79. Dathe, M.; Wieprecht, T.; Nikolenko, H.; Handel, L.; Maloy, W.L.; MacDonald, D.L.; Beyermann, M.; Bienert, M. Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Lett., 1997, 403, 208-212.
80. Alvarez-Bravo, J.; Kurata, S.; Natori, S. Novel synthetic antimicrobial peptides effective against methicillin-resistant Staphylococcus aureus. Biochem. J., 1994, 302 (Pt 2), 535-538.
81. Ellerby, H.M.; Arap, W.; Ellerby, L.M.; Kain, R.; Andrusiak, R.; Rio, G.D.; Krajewski, S.; Lombardo, C.R.; Rao, R.; Ruoslahti, E.; Bredesen, D.E.; Pasqualini, R. Anti-cancer activity of targeted proapoptotic peptides. Nat. Med., 1999, 5, 1032-1038.
82. Bowman, M.C.; Ballard, T.E.; Ackerson, C.J.; Feldheim, D.L.; Margolis, D.M.; Melander, C. Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc., 2008, 130, 6896-6897.
83. Cheng, Z.; Wu, Y.; Xiong, Z.; Gambhir, S.S.; Chen, X. Nearinfrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug. Chem., 2005, 16, 1433-1441.
84. Huang, Y.F.; Liu, H.; Xiong, X.; Chen, Y.; Tan, W. Nanoparticlemediated IgE-receptor aggregation and signaling in RBL mast cells. J. Am. Chem. Soc., 2009, 131, 17328-17334.
85. Kaittanis, C.; Santra, S.; Perez, J.M. Role of nanoparticle valency in the nondestructive magnetic-relaxation-mediated detection and magnetic isolation of cells in complex media. J. Am. Chem. Soc., 2009, 131, 12780-12791.
86. Wang, J.; Tian, S.; Petros, R.A.; Napier, M.E.; Desimone, J.M. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc., 2010, 132, 11306-11313.
87. Jokerst, J.V.; Lobovkina, T.; Zare, R.N.; Gambhir, S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond), 2011, 6, 715-728.
88. Kawano, T.; Yamagata, M.; Takahashi, H.; Niidome, Y.; Yamada, S.; Katayama, Y.; Niidome, T. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J. Control. Release, 2006, 111, 382-389.
89. Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2, 750-763.
90. Pastorino, F.; Brignole, C.; Marimpietri, D.; Cilli, M.; Gambini, C.; Ribatti, D.; Longhi, R.; Allen, T.M.; Corti, A.; Ponzoni, M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res., 2003, 63, 7400-7409.
91. Garde, S.V.; Forte, A.J.; Ge, M.; Lepekhin, E.A.; Panchal, C.J.; Rabbani, S.A.; Wu, J.J. Binding and internalization of NGRpeptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs, 2007, 18, 1189-1200.
92. Pagnan, G.; Stuart, D.D.; Pastorino, F.; Raffaghello, L.; Montaldo, P.G.; Allen, T.M.; Calabretta, B.; Ponzoni, M. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J. Natl. Cancer Inst., 2000, 92, 253-261.
93. Schulz, G.; Cheresh, D.A.; Varki, N.M.; Yu, A.; Staffileno, L.K.; Reisfeld, R.A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res., 1984, 44, 5914-5920.
94. Brignole, C.; Pastorino, F.; Marimpietri, D.; Pagnan, G.; Pistorio, A.; Allen, T.M.; Pistoia, V.; Ponzoni, M. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst., 2004, 96, 1171-1180.
95. Raffaghello, L.; Pagnan, G.; Pastorino, F.; Cosimo, E.; Brignole, C.; Marimpietri, D.; Montaldo, P.G.; Gambini, C.; Allen, T.M.; Bogenmann, E.; Ponzoni, M. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int. J. Cancer., 2003, 104, 559-567.
96. Pastorino, F.; Brignole, C.; Di Paolo, D.; Nico, B.; Pezzolo, A.; Marimpietri, D.; Pagnan, G.; Piccardi, F.; Cilli, M.; Longhi, R.; Ribatti, D.; Corti, A.; Allen, T.M.; Ponzoni, M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res., 2006, 66, 10073-10082.
97. Rowinsky, E.K.; Cazenave, L.A.; Donehower, R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 1990, 82, 1247-1259.
98. Belotti, D.; Vergani, V.; Drudis, T.; Borsotti, P.; Pitelli, M.R.; Viale, G.; Giavazzi, R.; Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 1996, 2, 1843-1849.
99. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 2001, 37, 1590-1598.
100. Kastantin, M.; Ananthanarayanan, B.; Karmali, P.; Ruoslahti, E.; Tirrell, M. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir, 2009, 25, 7279-7286.
101. Zhao, B.J.; Ke, X.Y.; Huang, Y.; Chen, X.M.; Zhao, X.; Zhao, B.X.; Lu, W.L.; Lou, J.N.; Zhang, X.; Zhang, Q. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J. Drug Target, 2011, 19, 382-390.
102. Yang, Z.L.; Li, X.R.; Yang, K.W.; Liu, Y. Amphotericin B-loaded poly(ethylene glycol)-poly(lactide) micelles: preparation, freezedrying, and in vitro release. J. Biomed. Mater. Res. A., 2008, 85, 539-546.
103. Nam, Y.S.; Kang, H.S.; Park, J.Y.; Park, T.G.; Han, S.H.; Chang, I.S. New micelle-like polymer aggregates made from PEI-PLGA diblock copolymers: micellar characteristics and cellular uptake. Biomaterials, 2003, 24, 2053-2059.
104. Cabral, H.; Nishiyama, N.; Kataoka, K. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J. Control. Release, 2007, 121, 146-155.
105. Yasugi, K.; Nagasaki, Y.; Kato, M.; Kataoka, K. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier. J. Control. Release, 1999, 62, 89-100.
106. Kim, D.W.; Kim, S.Y.; Kim, H.K.; Kim, S.W.; Shin, S.W.; Kim, J.S.; Park, K.; Lee, M.Y.; Heo, D.S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced nonsmall-cell lung cancer. Ann. Oncol., 2007, 18, 2009-2014.
107. Cortes, J.E.; Pazdur, R. Docetaxel. J. Clin. Oncol., 1995, 13, 2643-2655.
108. Wang, X.; Wang, Y.; Chen, X.; Wang, J.; Zhang, X.; Zhang, Q. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J. Control. Release, 2009, 139, 56-62.
109. Tamm, I.; Dorken, B.; Hartmann, G. Antisense therapy in oncology: new hope for an old idea? Lancet, 2001, 358, 489-497.
110. Kraemer, K.; Fuessel, S.; Schmidt, U.; Kotzsch, M.; Schwenzer, B.; Wirth, M.P.; Meye, A. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res., 2003, 9, 3794-3800.
111. Li, H.; Wang, J.; Zhou, T.; Zhang, Y.; Zhang, Z. An investigation of the effects of nanosize delivery system for antisense oligonucleotide on esophageal squamous cancer cells. Cancer Biol. Ther., 2008, 7, 1852-1859.
112. Chen, Y.; Sen, J.; Bathula, S.R.; Yang, Q.; Fittipaldi, R.; Huang, L. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm., 2009, 6, 696-705.
113. Chen, Y.; Wu, J.J.; Huang, L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol. Ther., 2010, 18, 828-834.
114. Abaza, M.S.; Al-Saffar, A.; Al-Sawan, S.; Al-Attiyah, R. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol., 2008, 29, 287-303.
115. Pastorino, F.; Brignole, C.; Marimpietri, D.; Pagnan, G.; Morando, A.; Ribatti, D.; Semple, S.C.; Gambini, C.; Allen, T.M.; Ponzoni, M. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin. Cancer Res., 2003, 9, 4595-4605.
116. Adar, L.; Shamay, Y.; Journo, G.; David, A. Pro-apoptotic peptidepolymer conjugates to induce mitochondrial-dependent cell death. Polym.Adv. Technol., 2010, 22, 199-208.
117. Takara, K.; Hatakeyama, H.; Ohga, N.; Hida, K.; Harashima, H. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int. J. Pharm., 2010, 396, 143-148.
118. Oostendorp, M.; Douma, K.; Hackeng, T.M.; Dirksen, A.; Post, M.J.; van Zandvoort, M.A.; Backes, W.H. Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGRlabeled paramagnetic quantum dots. Cancer Res., 2008, 68, 7676-7683.
119. von Wallbrunn, A.; Waldeck, J.; Holtke, C.; Zuhlsdorf, M.; Mesters, R.; Heindel, W.; Schafers, M.; Bremer, C. In vivo optical imaging of CD13/APN-expression in tumor xenografts. J. Biomed. Opt., 2008, 13, 011007.
120. Wang, R.E.; Niu, Y.; Wu, H.; Amin, M.N.; Cai, J. Development of NGR peptide-based agents for tumor imaging. Am. J. Nucl. Med. Mol. Imaging, 2011, 1, 36-46.
121. Walling, M.A.; Novak, J.A.; Shepard, J.R. Quantum dots for live cell and in vivo imaging. Int. J. Mol. Sci., 2009, 10, 441-491.
122. Ekimov AI.; Onushchenko AA. Quantum size effect in threedimensional microscopic semiconductor crystals.;ETATS-UNIS, Society of Photo-Optical Instrumentation Engineers: Bellingham, WA, 2005.
123. Akerman, M.E.; Chan, W.C.; Laakkonen, P.; Bhatia, S.N.; Ruoslahti, E. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 12617-12621.
124. Ballou, B.; Lagerholm, B.C.; Ernst, L.A.; Bruchez, M.P.; Waggoner, A.S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem., 2004, 15, 79-86.
125. Dahan, M.; Levi, S.; Luccardini, C.; Rostaing, P.; Riveau, B.; Triller, A. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science, 2003, 302, 442-445.
126. Howarth, M.; Liu, W.; Puthenveetil, S.; Zheng, Y.; Marshall, L.F.; Schmidt, M.M.; Wittrup, K.D.; Bawendi, M.G.; Ting, A.Y. Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nat. Methods, 2008, 5, 397-399.
127. Buehler, A.; van Zandvoort, M.A.; Stelt, B.J.; Hackeng, T.M.; Schrans-Stassen, B.H.; Bennaghmouch, A.; Hofstra, L.; Cleutjens, J.P.; Duijvestijn, A.; Smeets, M.B.; de Kleijn, D.P.; Post, M.J.; de Muinck, E.D. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2681-2687.
128. Son, S.; Singha, K.; Kim, W.J. Bioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier. Biomaterials, 2010, 31, 6344-6354.
129. Zimmer, J.P.; Kim, S.W.; Ohnishi, S.; Tanaka, E.; Frangioni, J.V.; Bawendi, M.G. Size series of small indium arsenide-zinc selenide core-shell nanocrystals and their application to in vivo imaging. J. Am. Chem. Soc., 2006, 128, 2526-2527.
130. Pons, T.; Pic, E.; Lequeux, N.; Cassette, E.; Bezdetnaya, L.; Guillemin, F.; Marchal, F.; Dubertret, B. Cadmium-free CuInS2/ZnS quantum dots for sentinel lymph node imaging with reduced toxicity. ACS Nano, 2010, 4, 2531-2538.
131. Kim, S.; Park, J.; Kim, T.; Jang, E.; Jun, S.; Jang, H.; Kim, B.; Kim, S.W. Reverse type-I ZnSe/InP/ZnS core/shell/shell nanocrystals: cadmium-free quantum dots for visible luminescence. Small, 2011, 7, 70-73.
132. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Itty Ipe, B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25, 1165-1170.